- Home
- BYD vs JAZZ Comparison
BYD vs JAZZ Comparison
Compare BYD & JAZZ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BYD
- JAZZ
- Stock Information
- Founded
- BYD 1973
- JAZZ 2003
- Country
- BYD United States
- JAZZ Ireland
- Employees
- BYD N/A
- JAZZ N/A
- Industry
- BYD Hotels/Resorts
- JAZZ Biotechnology: Pharmaceutical Preparations
- Sector
- BYD Consumer Discretionary
- JAZZ Health Care
- Exchange
- BYD Nasdaq
- JAZZ Nasdaq
- Market Cap
- BYD 5.9B
- JAZZ 6.1B
- IPO Year
- BYD 1993
- JAZZ 2007
- Fundamental
- Price
- BYD $71.82
- JAZZ $97.78
- Analyst Decision
- BYD Buy
- JAZZ Strong Buy
- Analyst Count
- BYD 16
- JAZZ 13
- Target Price
- BYD $93.73
- JAZZ $181.85
- AVG Volume (30 Days)
- BYD 908.5K
- JAZZ 1.3M
- Earning Date
- BYD 04-24-2025
- JAZZ 05-06-2025
- Dividend Yield
- BYD 1.01%
- JAZZ N/A
- EPS Growth
- BYD 9.82
- JAZZ 49.21
- EPS
- BYD 6.13
- JAZZ 7.51
- Revenue
- BYD $3,961,238,000.00
- JAZZ $4,064,808,000.00
- Revenue This Year
- BYD $1.62
- JAZZ $7.60
- Revenue Next Year
- BYD $2.83
- JAZZ $3.47
- P/E Ratio
- BYD $11.69
- JAZZ $13.00
- Revenue Growth
- BYD 6.06
- JAZZ 5.76
- 52 Week Low
- BYD $49.34
- JAZZ $95.49
- 52 Week High
- BYD $80.50
- JAZZ $148.06
- Technical
- Relative Strength Index (RSI)
- BYD 62.90
- JAZZ 33.01
- Support Level
- BYD $68.98
- JAZZ $97.50
- Resistance Level
- BYD $72.18
- JAZZ $120.67
- Average True Range (ATR)
- BYD 1.75
- JAZZ 4.33
- MACD
- BYD 0.59
- JAZZ -0.53
- Stochastic Oscillator
- BYD 95.51
- JAZZ 1.21
About BYD Boyd Gaming Corporation
Boyd Gaming Corp is a multi-jurisdictional gaming company. The company operates wholly-owned gaming entertainment properties (casino space, slot machines, table games, and hotel rooms) in Nevada, Illinois, Indiana, Iowa, Kansas, Louisiana, Mississippi, Missouri, Ohio, and Pennsylvania. Geographical regions separate its business segments: Las Vegas Locals, Downtown Las Vegas, Midwest and South, and Online. Midwest and South hold the key number of entertainment properties, and it generate the majority of sales for the company.
About JAZZ Jazz Pharmaceuticals plc (Ireland)
Jazz Pharmaceuticals is an Ireland-domiciled biopharmaceutical firm focused primarily on treatments for sleeping disorders and oncology. Jazz has nine approved drugs across neuroscience and oncology indications; its portfolio includes Xyrem and Xywav for narcolepsy, Zepzelca for the treatment of metastatic small cell lung cancer, Rylaze for acute lymphoblastic leukemia, and Vyxeos for acute myeloid leukemia. In May 2021, Jazz acquired GW Pharmaceuticals and gained its leading product, Epidiolex for the treatment of severe, rare forms of epilepsy.